chr19-49697380-T-G
Variant summary
Our verdict is Likely benign. Variant got -5 ACMG points: 0P and 5B. BS1_SupportingBS2
The NM_001199753.2(CPT1C):โc.196T>Gโ(p.Phe66Val) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000385 in 1,614,036 control chromosomes in the GnomAD database, including 1 homozygotes. In-silico tool predicts a benign outcome for this variant. 14/23 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (โ โ ).
Frequency
Consequence
NM_001199753.2 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -5 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
CPT1C | NM_001199753.2 | c.196T>G | p.Phe66Val | missense_variant | 4/20 | ENST00000598293.6 | NP_001186682.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
CPT1C | ENST00000598293.6 | c.196T>G | p.Phe66Val | missense_variant | 4/20 | 2 | NM_001199753.2 | ENSP00000473028 | P1 |
Frequencies
GnomAD3 genomes AF: 0.000230 AC: 35AN: 152156Hom.: 0 Cov.: 31
GnomAD3 exomes AF: 0.000239 AC: 60AN: 251484Hom.: 0 AF XY: 0.000258 AC XY: 35AN XY: 135912
GnomAD4 exome AF: 0.000402 AC: 587AN: 1461880Hom.: 1 Cov.: 31 AF XY: 0.000396 AC XY: 288AN XY: 727238
GnomAD4 genome AF: 0.000230 AC: 35AN: 152156Hom.: 0 Cov.: 31 AF XY: 0.000202 AC XY: 15AN XY: 74326
ClinVar
Submissions by phenotype
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Jan 04, 2022 | The c.196T>G (p.F66V) alteration is located in exon 4 (coding exon 2) of the CPT1C gene. This alteration results from a T to G substitution at nucleotide position 196, causing the phenylalanine (F) at amino acid position 66 to be replaced by a valine (V). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Hereditary spastic paraplegia 73 Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | May 24, 2023 | This sequence change replaces phenylalanine, which is neutral and non-polar, with valine, which is neutral and non-polar, at codon 66 of the CPT1C protein (p.Phe66Val). This variant is present in population databases (rs201119466, gnomAD 0.04%), and has an allele count higher than expected for a pathogenic variant. This variant has not been reported in the literature in individuals affected with CPT1C-related conditions. ClinVar contains an entry for this variant (Variation ID: 640926). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variantยฌโ is likely to be tolerated. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at